Adaptimmune Therapeutics PLC Quarterly Revenues in USD from Q1 2023 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
Summary
Adaptimmune Therapeutics PLC quarterly Revenues history and growth rate from Q1 2023 to Q3 2024.
  • Adaptimmune Therapeutics PLC Revenues for the quarter ending September 30, 2024 was $40.9M, a 459% increase year-over-year.
Revenues, Quarterly (USD)
Revenues, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $40.9M +$33.6M +459% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 $128M +$123M +2400% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 $5.68M -$41.9M -88.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q3 2023 $7.32M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 $5.13M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 $47.6M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.